Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 114-128 , April 2003

Positron emission tomography and single-photon emission computed tomography in substance abuse research

References 

  1. Fowler JS, Volkow ND. PET imaging studies in drug abuse. Clin Toxicol. 1998;36:163–174
  2. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988;242:715–723
  3. DiChiara G, Imperato A. Drugs abused by humans preferentially increasesynaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Nat Acad Sci USA. 1988;85:5274–5278
  4. Volkow ND, Fowler JS, Gatley SJ, et al.  PET evaluation of the dopamine system of the human brain. J Nucl Med. 1996;37:1242–1256
  5. Ritz MC, Lamb RJ, Goldberg SR, et al.  Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219–1223
  6. Fowler JS, Volkow ND, Wang GJ, et al.  [11C]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol. 2001;28:561–572
  7. Ritchie JM, Greene NM. Local anesthetics. In:  Gilman A,  Goodman LS editor. The Pharmacological Basis of Therapeutics. New York: Pergamon Press,; 1990;p. 311; chapt 15
  8. Volkow ND, Mullani N, Gould KL, et al.  Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry. 1988;152:641–648
  9. Holman B, Carvalho P, Mendelson J, et al.  Brain perfusion is abnormal in cocaine-dependent polydrug users: A study using technetium-99m-HMPAO and SPECT. J Nucl Med. 1991;32:1206–1210
  10. Wallace E, Wisniewski G, Zubal G, et al.  Acute cocaine effects on absolute cerebral blood flow. Psychopharmacology. 1996;128:17–20
  11. Baxter LR, Schwartz JM, Phelps ME, et al.  Localization of neurochemical effects of cocaine and other stimulants in the human brain. J Clin Psychiatry. 1988;49:23–26
  12. Fowler JS, Volkow ND, Wolf AP, et al.  Mapping cocaine binding in human and baboon brain in vivo. Synapse. 1989;4:371–377
  13. Volkow ND, Wang G-J, Fischman M, et al.  Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386:827–830
  14. Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: Effect of dose and interval. J Exp Anal Behav. 1973;20:119–129
  15. Logan J, Volkow ND, Fowler JS, et al.  Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET. Synapse. 1997;27:347–356
  16. Volkow ND, Wang GJ, Fischman MW, et al.  Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 2000;67:1507–1515
  17. Volkow ND, Wang GJ, Fowler JS, et al.  Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J Pharmacol Exper Therap. 1999;291:409–415
  18. Volkow ND, Fowler JS, Wolf AP, et al.  Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990;147:719–724
  19. Volkow ND, Wang GJ, Fowler JS, et al.  Decreased striatal dopaminergic responsivity in detoxified cocaine abusers. Nature. 1997;386:830–833
  20. Volkow ND, Fowler JS, Wolf AP, et al.  Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psych. 1991;148:621–626
  21. Volkow ND, Hitzemann R, Wang GJ, et al.  Long-term frontal brain metabolic changes in cocaine dependence and withdrawal. Am J Psych. 1992;148:621–626
  22. Volkow ND, Fowler JS, Wang GJ, et al.  Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14:169–177
  23. Insel TR. Towards a neuroanatomy of obsessive compulsive disorder. Arch Gen Psychiatry. 1992;49:739–744
  24. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive. Cerebral Cortex. 2000;10:318–325
  25. Zubieta JK, Gorelick DA, Stauffer R, et al.  Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 1996;2:1225–1229
  26. Jacobsen LK, Staley JK, Malison RT, et al.  Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry. 2000;157:1134–1140
  27. Volkow ND, Fowler JS, Wolf AP, et al.  Distribution of 11C-cocaine in human heart, lungs, liver and adrenals. A dynamic PET study. J Nucl Med. 1992;33:521–525
  28. Kloner RA, Alker K, Hale S. The effect of acute and chronic cocaine use on the heart. Circulation. 1992;85:407–419
  29. Fowler JS, Ding Y-S, Volkow N, et al.  PET studies of cocaine inhibition of the myocardial norepinephrine uptake. Synapse. 1994;16:312–317
  30. Melon PG, Boyd CJ, McVey S, et al.  Effects of active chronic cocaine use on cardiac sympathetic neuronal function assessed by C-11 hydroxyephedrine. J Nucl Med. 1997;38:451–456
  31. Seiden LS, Sabol KE. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destructions. NIDA Res Monograph. 1996;163:251–276
  32. McCann UD, Wong DF, Yokoi F, et al.  Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35 428. J Neurosci. 1998;18:8417–8422
  33. Volkow ND, Chang L, Wang GJ. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377–382
  34. Volkow ND, Chang L, Wang GJ, et al.  Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414–9418
  35. Sekine Y, Iyo M, Ouchi Y, et al.  Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158:1206–1214
  36. Volkow ND, Chang L, Wang GJ, et al.  Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. Am J Psychiatry. 2001;158:2015–2021
  37. Volkow ND, Chang L, Wang GJ, et al.  Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry. 2001;158:383–389
  38. Huether G, Zhou D, Ruther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners. J Neural Transm. 1997;104:771–794
  39. Ricaurte GA, Forno LS, Wilson MA, et al.  (+/−)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988;260:51–55
  40. McCann UD, Ricaurte GA, Molliver ME. “Ecstasy” and serotonin neurotoxicity: New findings raise more questions. Arch Gen Psychiatry. 2001;58:907–908
  41. McCann UD, Szabo Z, Scheffel U, et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings. Lancet. 1998;352:1433–1437
  42. Reneman L, Lavalaye J, Schmand B, et al.  Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”): Preliminary findings. Arch Gen Psychiatry. 2001;58:901–906
  43. Buchert R, Obrocki J, Thomasius R, et al.  Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET. Nucl Med Commun. 2001;22:889–897
  44. Chang L, Grob CS, Ernst T, et al.  Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: A co-registered SPECT and MRI study. Psychiatry Res. 2000;98:15–28
  45. Volkow ND, Hitzemann R, Wolf AP, et al.  Acute effects of ethanol on regional brain glucose metabolism and transport. Psychiatry Res. 1990;35:39–48
  46. Moselhy HF, Georgiou G, Kahn A. Frontal lobe changes in alcoholism: A review of the literature. Alcohol Alcoholism. 2001;36:357–368
  47. Volkow ND, Wang G-J, Hitzemann R, et al.  Recovery of brain glucose metabolism in detoxified alcoholics. Am J Psychiatry. 1994;151:178–183
  48. Volkow ND, Wang G-J, Hitzemann R, et al.  Decreased cerebral response to inhibitory neurotransmission in alcoholics. Am J Psychiatry. 1993;150:417–422
  49. Volkow ND, Wang GJ, Begleiter H, et al.  Regional brain metabolic response to lorazepam in subjects at risk for alcoholism. Alcohol Clin Experi Res. 1995;19:510–516
  50. Wang GJ, Volkow ND, Franceschi D, et al.  Regional brain metabolism during alcohol intoxication. Alcohol Clin Exp Res. 2000;24:822–829
  51. Mann K, Agartz I, Harper C, et al.  Neuroimaging in alcoholism: Ethanol and brain damage. Alcohol Clin Exp Res. 2001;25:104S–109S review
  52. Gilman S, Koeppe RA, Adams K, et al.  Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics. Ann Neurol. 1996;40:163–171
  53. Abi-Dargham A, Krystal JH, Anjilvel S, et al.  Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. Am J Psychiatry. 1998;155:1550–1555
  54. Lingford-Hughes AR, Acton PD, Gacinovic S, et al.  Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy. Br J Psychiatry. 1998;173:116–122
  55. Volkow ND, Wang GJ, Fowler JS, et al.  Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res. 1996;20:1594–1598
  56. Repo E, Kuikka JT, Bergstrom KA, et al.  Dopamine transporter and D2-receptor density in late-onset alcoholism. Psychopharmacology (Berl). 1999;147:314–318
  57. Guardia J, Catafau AM, Batlle F, et al.  Striatal dopaminergic D(2) receptor density measured by [(123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry. 2000;157:127–129
  58. Laine TP, Ahonen A, Torniainen P, et al.  Dopamine transporters increase in human brain after alcohol withdrawal. Mol Psychiatry. 1999;4:189–191 104-105
  59. Volkow ND, Wang GJ, Fowler JS, et al.  Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res. 1996;20:1594–1598
  60. Zahniser NR, Doolen S. Chronic and acute regulation of Na(+)/Cl(−)-dependent neurotransmitter transporters: Drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol Ther. 2001;92:21–55
  61. Heinz A, Ragan P, Jones-DW , et al.  Reduced central serotonin transporters in alcoholism. Am J Psychiatry. 1998;155:1544–1549
  62. Gilman S, Koeppe RA, Adams KM, et al.  Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography. Ann Neurol. 1998;44:326–333
  63. Wang GJ, Volkow ND, Fowler JS, et al.  Regional cerebral metabolism in female alcoholics of moderate severity does not differ from that of controls. Alcohol Clin Exp Res. 1998;22:1850–1854
  64. Lingford-Hughes AR, Acton PD, Gacinovic S, et al.  Levels of gamma-aminobutyric acid-benzodiazepine receptors in abstinent, alcohol-dependent women: Preliminary findings from an 123I-iomazenil single photon emission tomography study. Alcohol Clin Exp Res. 2000;24:1449–1455
  65. Catafau AM, Etcheberrigaray A, Perez de los Cobos J, et al.  Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification. J Nucl Med. 1999;40:19–24
  66. Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: An epidemiological perspective for geneticists. Oncogene. 2002;21:7307–7325
  67. Domino EF. Brain Imaging of Nicotine and Tobacco Smoking. Michigan, Ann Arbor: NPP Books; 1995;
  68. Sihver W, Nordberg A, Langstrom B, et al.  Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res. 2000;113:143–157
  69. Volkow ND, Fowler JS, Ding YS, et al.  Imaging the neurochemistry of nicotine actions: studies with positron emission tomography. Nicotine Tob Res. 1999;1(suppl 2):S127–S132 discussion S139-40
  70. Ding YS, Volkow ND, Logan J, et al.  Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette. Synapse. 2000;35:235–237
  71. Molina PE, Ding YS, Carroll FI, et al.  Fluoro-norchloroepibatidine: Preclinical assessment and acute toxicity. Nucl Med Biol. 1997;24:743–747
  72. Ding YS, Liu N, Wang T, et al.  Synthesis and evaluation of 6-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine as a PET tracer for nicotinic acetylcholine receptors. Nucl Med Biol. 2000;27:381–389
  73. Fujita M, Seibyl J, Vaupel DB, et al.  Whole body distribution, radiation absorbed dose and brain SPET imaging with [123I]5-iodo-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imag. 2002;2:183–190
  74. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: From genes to behavior. Ann Rev Neurosci. 1999;22:197–217
  75. Fowler JS, Logan J, Volkow ND, et al.  Monoamine oxidase: Radiotracer development and human studies. Methods. 2002;27:263–277
  76. Fowler JS, Wang G-J, Volkow ND, et al.  Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379:733–736
  77. Fowler JS, Volkow ND, Wang G-J, et al.  Brain monoamine oxidase A inhibition in cigarette smokers. Proc Nat Acad Sci USA. 1996;93:14065–14069
  78. Rose JE, Behm FM, Ramsey C, et al.  Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res. 2001;3:383–390
  79. Khalil AA, Steyn S, Castagnoli N. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol. 2000;13:31–35
  80. Dagher A, Bleicher C, Aston JA, et al.  Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse. 2001;42:48–53
  81. Salokangas RK, Vilkman H, Ilonen T, et al.  High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry. 2000;157:632–634
  82. Staley JK, Krishnan-Sarin S, Zoghbi S, et al.  Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41:275–284
  83. Martin-Soelch C, Magyar S, Kunig G, et al.  Changes in brain activation associated with reward processing in smokers and nonsmokers. A positron emission tomography study. Exp Brain Res. 2001;139:278–286
  84. Ernst M, Matochik JA, Heishman SJ, et al.  Effect of nicotine on brain activation during performance of a working memory task. Proc Natl Acad Sci USA. 2001;98:4728–4733
  85. Domino EE, Minoshima S, Guthrie SK, et al.  Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers. Neuroscience. 2000;101:277–282
  86. Zubieta J, Lombardi U, Minoshima S, et al.  Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry. 2001;49:906–913
  87. Dhawan BN, Cesselin F, Raghubir R, et al.  International Union of Pharmacology, XII. Classification of opioid receptors. Pharmacol Rev. 1996;48:567–592
  88. London ED, Cascella NG, Wong DF, et al.  Cocaine induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine-18]fluorodeoxyglucose. Arch Gen Psychiatry. 1990;47:567–574
  89. London ED, Broussolle EPM, Links JM, et al.  Morphine-induced metabolic changes in human brain: Studies with positron emission tomography and [fluorine-18]fluorodeoxyglucose. Arch Gen Psychiatry. 1990;47:73–81
  90. Galynker IL, Watras-Ganz S, Miner C, et al.  Cerebral metabolism in opiate-dependent subjects: Effects of methadone maintenance. Mt Sinai J Med. 2000;67:381–387
  91. Danos P, Kasper S, Grunwald F, et al.  Pathological regional cerebral blood flow in opiate-dependent patients during withdrawal: A HMPAO-SPECT study. Neuropsychobiology. 1998;37:194–199
  92. Martin-Soelch C, Chevalley AE, Kunig G, et al.  Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci. 2001;14:1360–1368
  93. Daglish MR, Weinstein A, Malizia AL, et al.  Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. Am J Psychiatry. 2001;158:1680–1686
  94. Sell LA, Morris JS, Bearn J, et al.  Neural responses associated with cue evoked emotional states and heroin in opiate addicts. Drug Alcohol Depend. 2000;60:207–216
  95. Kling MA, Carson RE, Borg L, et al.  Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295:1070–1076
  96. Zubieta J, Greenwald MK, Lombardi U, et al.  Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: A preliminary study. Neuropsychopharmacology. 2000;23:326–334
  97. Wang GJ, Volkow ND, Fowler JS, et al.  Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology. 1997;16:174–182
  98. Herkenham M, Lynn AB, Little MD, et al.  Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932–1936
  99. Block RI, O'Leary DS, Hichwa RD, et al.  Cerebellar hypoactivity in frequent marijuana users. Neuroreport. 2000;11:749–753
  100. O'Leary DS, Block RI, Flaum M, et al.  Acute marijuana effects on rCBF and cognition: a PET study. Neuroreport. 2000;11:3835–3841
  101. O'Leary DS, Block RI, Koeppel JA, et al.  Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology. 2002;26:802–816
  102. Mathew RI, Wilson WH, Turkington TG, et al.  Cerebellar activity and disturbed time sense after THC. Brain Res. 1998;797:183–189
  103. Volkow ND, Gillespie H, Mullani N, et al.  Cerebellar metabolic activation by delta-9-tetrahydrocannabinol in human brain: A study with positron emission tomography and F-18-2 fluoro-2-deoxyglucose. Psychiatry Res. 1991;40:69–78
  104. Volkow ND, Gillespie H, Mullani N, et al.  Brain glucose metabolism in chronic marijuana users during baseline and during marijuana intoxication. Psychiatry Res. 1996;67:29–38
  105. Gatley SJ, Lan R, Volkow ND, et al.  Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem. 1998;70:417–423
  106. Okada S, Yamanouchi N, Kodama K, et al.  Regional cerebral blood flow abnormalities in chronic solvent abusers. Psychiatry Clin Neurosci. 1999;53:351–356
  107. Kucuk NO, Kilic EO, Ibis E, et al.  Brain SPECT findings in long-term inhalant abuse. Nucl Med Commun. 2000;21:769–773
  108. Gerasimov M, Ferrieri R, Schiffer WK, et al.  Study of brain uptake and biodistribution of [11C]toluene in non-human primates. Life Sci. 2002;70:2811–2828
  109. Blum K, Cull JG, Braverman ER, et al.  Reward deficiency syndrome. Am Scientist. 1996;84:132–145
  110. Wang GJ, Volkow ND, Logan J, et al.  Brain dopamine and obesity. Lancet. 2001;357:354–357
  111. Volkow ND, Wang GJ, Fowler JS, et al.  Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry. 1999;156:1440–1443
  112. Thanos PK, Volkow ND, Freimuth P, et al.  Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem. 2001;78:1094–1103
  113. Thanos PK, Taintor NB, Alexoff D, et al.  In vivo comparative imaging of dopamine D2 knockout and wild-type mice with 11C-raclopride and microPET. J Nucl Med. 2002;43:1570–1577
  114. Cherry SR. MicroPET: A high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci. 1997;44:1161–1166
  115. O'Brien CP. A range of research-based pharmacotherapies for addiction. Science. 1997;278:66–70
  116. Dewey SL, Smith GW, Logan J, et al.  GABAergic inhibition of endogeneous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci. 1992;12:3773–3780
  117. Dewey SL, Morgan AE, Ashby CR, et al.  A novel GABAergic strategy for the treatment of cocaine addiction. Synapse. 1998;30:119–129
  118. Dewey SL, Brodie JD, Gerasimov M, et al.  A pharmacologic strategy for the treatment of nicotine addiction. Synapse. 1999;31:76–86

☆ Address reprint requests to Nora D. Volkow, Medical Department, Brookhaven National Laboratory, Upton, NY 11973.

☆☆ This work was carried out at Brookhaven National Laboratory under contract DE-AC02-98CH10886 and with the U. S. Department of Energy and supported by its Office of Biological and Environmental Research and also by the National Institutes of Health (National Institute on Drug Abuse and National Institutes of Neurological Diseases and Stroke).

★ 0001-2998/03/3302-0004$30.00/0

PII: S0001-2998(03)70016-6

doi: 10.1053/snuc.2003.127300

Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 114-128 , April 2003

Article Tools

* Image Usage & Resolution